Amgen grabs the axe, chops up to 2,600 jobs
(UPDATED: See below.)
The biotech colossus Amgen, stung by safety and regulatory issues that hit hard at sales of its core anemia drugs, announced today that it will cut its headcount between 12 percent and 14 percent, ratchet back on new plant construction, close production operations and prioritize its research spending. The giant biotech said these measures will yield savings of up to $1.3 billion by next year.
The restructuring is the first in Amgen’s history, and virtually… Continue Reading